Mirimus, Inc. announced a strategic collaboration with Biogen Inc. focused on the development of RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications. Terms of the collaboration between Mirimus and Biogen are undisclosed. Mirimus was established in 2010 with the goal of creating a scalable and cost-effective pipeline for model generation and therapeutic development by harnessing the power of RNAi and CRISPR technologies, including development of animal models crucial for preclinical evaluation of new therapeutics. Under the agreement, Mirimus will apply its expertise to engineer RNAi-based therapeutics that will be assessed by Biogen to determine feasibility in potential neurological disease settings. If feasibility is established, the companies will have the option to pursue pre-clinical development of the asset(s).